ESMO Reports Neoadjuvant Therapy for TNBC, Combination Checkpoint Inhibition, Artificial Intelligence & More

Oncology Times - OncTimes Talk

Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the ESMO 2024 Congress. Rebecca Dent, MD, Scientific Chair of the meeting, as well as Medical Oncologist and Deputy Chief Executive Officer at the National Cancer Center in Singapore (with a special interest in all aspects of triple-negative breast cancer), shared the key areas of progress covered by the meeting.